Inside the GLOW Blend: GHK-Cu, BPC-157 & TB-500

The short version

The GLOW blend is three separate peptides packaged together, each with its own scientific record and its own regulatory status. GHK-Cu (the copper tripeptide) has decades of cosmetic and cell-culture research and a handful of clinical topical studies. BPC-157 (the gastric-juice peptide) has a large and reproducible animal record for tendon and vascular healing but only three tiny human pilots. TB-500 (the thymosin fragment) has strong data for its parent protein on wound closure and cell migration, but most of that data uses the full 43-amino-acid protein, not the 7-mer commercial fragment. The three share no study that tests them together. The rationale for the combination is mechanistic — complementary pathways — and it is a hypothesis, not a confirmed result.

GHK-Cu: the skin and matrix constituent

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex; CAS 89030-95-5; INCI: Copper Tripeptide-1; MW approximately 402.9 Da) is the peptide that gives the GLOW blend its skin-renewal positioning. The GHK sequence occurs naturally within human type I collagen and circulates in plasma, where its levels decline with age ^[1]. As the copper(II) chelate, it acts as both a matrix-remodeling signal and a copper chaperone.

In dermal fibroblast cultures, GHK-Cu stimulates synthesis of collagen, dermatan sulfate (a structural glycosaminoglycan), chondroitin sulfate and the small matrix proteoglycan decorin at nanomolar concentrations ^[1]. It also tightens loose skin, improves elasticity and firmness, and reduces fine lines and wrinkles as documented in clinical topical studies ^[1]. The tissue-remodeling picture is broader: a foundational review established that GHK-Cu stimulates VEGF, FGF-2, NGF and metalloproteinase inhibitors (TIMPs) while suppressing TGF-beta-1 and TNF-alpha, and chemoattracts repair cells to the site ^[2]. Copper itself is a required cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin fibers into structural networks — one mechanistic route by which GHK-Cu may support skin architecture ^[2].

Regulatory status for GHK-Cu depends on the route and formulation: topical Copper Tripeptide-1 is a legal cosmetic ingredient used in a wide range of skincare products. Systemic GHK-Cu (injectable or IV) is a research-only application without any approved therapeutic indication.

BPC-157: the connective-tissue and angiogenesis constituent

BPC-157 (sequence GEPPPGKPADDAGLV; MW approximately 1419 Da) is a synthetic pentadecapeptide (15 amino acids) derived from a protein isolated from human gastric juice. Its two most important mechanistic contributions to the GLOW combination thesis are tendon-connective-tissue repair and angiogenesis.

In the foundational Achilles transection study, daily intraperitoneal BPC-157 at doses from 10 pg/kg to 10 μg/kg accelerated healing of a fully transected rat Achilles tendon across all measured endpoints: biomechanical load-to-failure, functional weight-bearing restoration, macroscopic tendon continuity and histological organization ^[3]. In vitro, it stimulated tendocyte (tendon fibroblast) outgrowth in culture ^[3]. The angiogenesis mechanism is molecularly defined: BPC-157 up-regulates VEGFR2 mRNA and protein, promotes VEGFR2 internalization, and activates the VEGFR2–Akt–eNOS cascade — increasing vessel density in chick chorioallantoic membrane, rat hind-limb ischemia, and human endothelial-cell models ^[4].

Human evidence: three small pilot studies (intraarticular knee pain, interstitial cystitis, and a 2-subject IV safety pharmacokinetics pilot). A 2025 narrative review concluded that no adverse events were reported in those pilots but that BPC-157 should be treated as investigational and used with caution until well-designed randomized controlled trials exist ^[7]. The FDA placed BPC-157 on a list of bulk drug substances not eligible for pharmacy compounding pending further evaluation in 2023.

WADA status: BPC-157 is a prohibited substance under the WADA Prohibited List's catch-all non-approved-substance and peptide categories.

TB-500: the cell-migration and anti-scarring constituent

TB-500 is the synthetic acetylated heptapeptide Ac-LKKTETQ (MW approximately 889 Da) corresponding to the actin-binding region of thymosin beta-4 (Tb4; gene TMSB4X; 43 amino acids). Tb4 is a naturally occurring G-actin-sequestering peptide found in most cells and platelets and released at sites of injury.

The molecular mechanism is established by X-ray crystallography: Tb4 forms a strict 1:1 complex with G-actin (globular monomeric actin) via its WH2 (WASP Homology 2) actin-interacting domain, sequestering the monomer and preventing it from polymerizing into filamentous actin ^[9]. Buffering the free actin pool this way enables the cytoskeletal remodeling that drives cells toward wounds and injury sites. In a rat full-thickness wound model, Tb4 increased re-epithelialization by 42% at day 4 and 61% at day 7 versus saline controls, raised collagen deposition, and increased angiogenesis ^[5]. As little as 10 pg stimulated keratinocyte and fibroblast migration 2–3-fold in cell-migration assays ^[5]. A review of Tb4's multi-functional biology confirmed reduced myofibroblast number (less scar-forming contracture), suppression of post-injury apoptosis and inflammation, platelet and macrophage release at injury sites, and clinical-development work in dermal wounds, corneal injury, and cardiac repair ^[8].

The commercial TB-500 fragment is the 7-mer Ac-LKKTETQ, not full-length Tb4. Most of the data above used full-length Tb4; whether the shorter fragment fully reproduces the parent protein's multi-domain biology is not established ^[8]. That gap is the honest TB-500 limitation that any reading of the blend must carry.

WADA status: thymosin beta-4 (and TB-500 as its actin-binding fragment) is prohibited under WADA Prohibited List class S2 (peptide hormones, growth factors, related substances and mimetics), banned at all times in and out of competition.

The combination thesis — and where it has not been tested

The rationale for combining the three peptides is mechanistic complementarity: GHK-Cu provides a matrix-building and remodeling signal at the level of dermal fibroblasts; BPC-157 provides a vascular and cytoprotective signal through VEGFR2-mediated angiogenesis; TB-500 provides a cell-migration and anti-scarring signal through G-actin sequestration. The three pathways do not obviously overlap, which is the intuitive basis for the combination.

The gap that this digest must state plainly: no controlled study has tested the three-peptide GLOW blend head-to-head against its individual components or against a placebo in any species. The combination pharmacokinetics are unstudied — the three constituents have different molecular weights, half-lives, and clearance routes, and whether co-formulation alters any of them is unknown. Copper chemistry (GHK-Cu's redox interactions at different pH levels) could in principle affect co-formulation stability with the other two peptides; this has not been characterized for the GLOW blend. The 2026 Sports Medicine review that most directly addresses the blend-adjacent evidence concluded that unapproved peptides including all three GLOW constituents show animal-model promise but scarce human safety data and potential for serious harm when used outside regulatory frameworks ^[6].

GLOW peptide stack context. The GLOW blend is sometimes described as a foundational stack to which other peptides are added. KLOW adds KPV (a tripeptide fragment of alpha-MSH with anti-inflammatory research activity in gut-inflammation models) to the GLOW base. The Wolverine blend uses BPC-157 and TB-500 without the GHK-Cu layer. These are distinct formulations with overlapping constituents; none of the combined stacks has been tested in a controlled trial.